Valacyclovir: Difference between revisions
Neil.m.young (talk | contribs) (Text replacement - "0 mg" to "0mg") |
ClaireLewis (talk | contribs) No edit summary |
||
| (2 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
==General== | ==General== | ||
*Type: inhibits DNA polymerase | *Type: [[Antiviral]], inhibits DNA polymerase | ||
*Dosage Forms: 500, 1000 | *Dosage Forms: 500, 1000 | ||
*Common Trade Names: Valtrex | *Common Trade Names: Valtrex | ||
| Line 19: | Line 19: | ||
==Special Populations== | ==Special Populations== | ||
*[[Drug Ratings in Pregnancy|Pregnancy Rating]]: | *[[Drug Ratings in Pregnancy|Pregnancy Rating]]: B | ||
*Lactation: | *Lactation: Excreted in breastmilk | ||
*Renal Dosing | *Renal Dosing | ||
** | **CrCl <10 mL/min: 500 mg/day PO | ||
*Hepatic Dosing: not defined | |||
*Hepatic Dosing | |||
==Contraindications== | ==Contraindications== | ||
| Line 33: | Line 30: | ||
==Adverse Reactions== | ==Adverse Reactions== | ||
===Serious=== | ===Serious=== | ||
*TTP, HUS (reported in advanced HIV and transplant patients) | |||
*Acute renal failure (especially if elderly or underlying renal disease) | |||
*Agitation, hallucinations, encephalopathy (higher risk in elderly) | |||
===Common=== | ===Common=== | ||
*Headache, dizziness | |||
*Nausea/vomiting, abdominal pain | |||
*Neutropenia, thrombocytopenia, leukopenia | |||
*Elevated LFTs | |||
*Nasopharyngitis | |||
*Dysmenorrhea | |||
*Depression | |||
*Rash | |||
*Alopecia | |||
*EM | |||
*Hypertension | |||
*Tachycardia | |||
*Tremor | |||
*Visual disturbance | |||
==Pharmacology== | ==Pharmacology== | ||
*Half-life: | *Half-life: 2-3.3hr | ||
*Metabolism: | *Metabolism: Hepatic | ||
*Excretion: | *Excretion: Urinary | ||
*Mechanism of Action: | *Mechanism of Action: converted to acyclovir, which competes with deoxyguanosine triphosphate for viral DNA polymerase to inhibit DNA synthesis and viral replication | ||
==See Also== | ==See Also== | ||
==References== | ==References== | ||
<references/> | |||
[[Category:Pharmacology]] | [[Category:Pharmacology]] | ||
[[Category:ID]] | |||
Latest revision as of 23:22, 23 September 2019
General
- Type: Antiviral, inhibits DNA polymerase
- Dosage Forms: 500, 1000
- Common Trade Names: Valtrex
Adult Dosing
HSV-1
- Acute episode: 2000mg PO BID x 1 day
- Suppression: 500mg PO Qday
Genital HSV
- 1st episode: 1000mg PO BID x 7-10 days, start within 48-72 hour of symptoms
- recurrence: 500mg PO BID x 3 days, alternative: 1000mg PO qday x 5 days
Shingles
- 1000mg PO TID x 7 days
Pediatric Dosing
Genital HSV
- ≥12 yrs same as adult dosing for adolescents
Special Populations
- Pregnancy Rating: B
- Lactation: Excreted in breastmilk
- Renal Dosing
- CrCl <10 mL/min: 500 mg/day PO
- Hepatic Dosing: not defined
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
- TTP, HUS (reported in advanced HIV and transplant patients)
- Acute renal failure (especially if elderly or underlying renal disease)
- Agitation, hallucinations, encephalopathy (higher risk in elderly)
Common
- Headache, dizziness
- Nausea/vomiting, abdominal pain
- Neutropenia, thrombocytopenia, leukopenia
- Elevated LFTs
- Nasopharyngitis
- Dysmenorrhea
- Depression
- Rash
- Alopecia
- EM
- Hypertension
- Tachycardia
- Tremor
- Visual disturbance
Pharmacology
- Half-life: 2-3.3hr
- Metabolism: Hepatic
- Excretion: Urinary
- Mechanism of Action: converted to acyclovir, which competes with deoxyguanosine triphosphate for viral DNA polymerase to inhibit DNA synthesis and viral replication